Wide Ranks

KZIA

Kazia Therapeutics Limited

5.46

Top Statistics
Market Cap 23 M Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 0.71 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -68.56 Enterprise / Revenue 2145569.80 Price To Sales Trailing12 Months 42460.86
Profitability
Profit Margins 0.00 % Operating Margins -148056740.00 %
Balance Sheet
Total Cash 3 M Total Cash Per Share 0.0140 Total Debt 359300
Total Debt To Equity 6.82 Current Ratio 0.71 Book Value Per Share 2.00
All Measures
Short Ratio 11.00 % Message Board Id finmb_401773 Shares Short Prior Month 31162
Return On Equity -1.86 City Sydney Uuid 1898cad7-893e-3eb8-a2ff-3751c401090e
Previous Close 5.55 First Trade Date Epoch Utc 915 M Book Value 2.00
Beta 2.08 Total Debt 359300 Volume 25367
Price To Book 2.73 Last Split Date 1 B Fifty Two Week Low 1.90
Total Cash Per Share 0.0140 Total Revenue 560 Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -148056740.00 %
Net Income To Common -15702666 Short Percent Of Float 0.0168 Implied Shares Outstanding 4 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 45700
Average Volume10days 45700 Total Cash 3 M Next Fiscal Year End 1 B
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 5.55 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 4.90 Open 5.54 Free Cashflow -6574324
State NSW Dividend Yield 0.00 % Return On Assets -0.4642
Time Zone Short Name EST Trailing Eps -6.58 Day Low 5.41
Address1 Three International Towers Shares Outstanding 4 M Price Hint 2
Target High Price 0.0000 Website https://www.kaziatherapeutics.com 52 Week Change -0.0250
Average Volume 142068 Recommendation Key none Forward Eps 0.0000
Compensation As Of Epoch Date 1 B Quick Ratio 32.00 % Last Split Factor 1:10
Regular Market Day High 5.80 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 6.82 Fifty Two Week High 15.80 Day High 5.80
Shares Short 18773 Regular Market Open 5.54 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 2145569.80 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0056 Operating Cashflow -12684881 Currency USD
Time Zone Full Name America/New_York Market Cap 23 M Is_nasdaq_100 False
Zip 2000 Quote Type EQUITY Industry Biotechnology
Long Name Kazia Therapeutics Limited Regular Market Day Low 5.41 Held Percent Institutions 0.0706
Current Price 5.46 Address2 Level 24 300 Barangaroo Avenue Enterprise To Ebitda -68.56
Financial Currency AUD Current Ratio 0.71 Gross Margins 100.00 %
Industry Disp Biotechnology Country Australia Float Shares 249 M
Two Hundred Day Average 3.72 Enterprise Value 1 B Price To Sales Trailing12 Months 42460.86
Forward PE 0.0000 Regular Market Volume 25367 Ebitda -17524020
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company.

The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma.

It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.

The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.

Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.